Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy

Abstract

A risk model for neutropenic complications was developed and validated in a large prospective cohort of patients who were beginning cancer chemotherapy that may guide the effective and cost-effective use of available supportive care.